BioNTech SE
Clinical trials sponsored by BioNTech SE, explained in plain language.
A biotechnology company developing immunotherapies, including mRNA-based vaccines and cancer treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- BioNTech launches first human test of mRNA herpes vaccine Results expected Oct 2026 (estimated)
- New antibody BNT351 enters first human trial for HIV Results expected Nov 2026 (estimated)
- New vaccine aims to stop colorectal cancer recurrence in High-Risk patients Results expected Nov 2026 (estimated) May already have reported ↗
- Can updated COVID-19 shots better protect High-Risk groups? Results expected Apr 2027 (estimated)
- New combo therapy takes on tough lung cancer Results expected Jun 2027 (estimated)
-
BioNTech's RNA cancer therapy trial halted early
Disease control Stopped earlyThis study tested an experimental RNA-based therapy called BNT142 in people with advanced solid tumors that have a specific protein called CLDN6. The goal was to see if it was safe and could shrink tumors. However, the trial was terminated early, so we don't have clear answers ab…
Phase 1/2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Pancreatic cancer combo trial halted after just one patient
Disease control Stopped earlyThis study aimed to see if adding the experimental drug BNT321 to standard chemotherapy (mFOLFIRINOX) after surgery could help prevent pancreatic cancer from coming back. It was designed for people whose tumors were fully removed. However, the trial was stopped early after enroll…
Phase 1/2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC